TIDMPRTC
PureTech Health PLC
08 July 2021
8 July 2021
PureTech Health plc
PureTech Founded Entity Sonde Health Announces Collaboration
with Qualcomm Technologies for Use of Vocal Biomarker Technology on
Qualcomm Snapdragon Mobile Platforms
PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the
"Company"), a clinical-stage biotherapeutics company, is pleased to
note that its Founded Entity, Sonde Health ("Sonde"), today
announced that it will collaborate with leading chipmaker Qualcomm
Technologies, Inc. ("Qualcomm") to optimize use of Sonde's vocal
biomarker technology on the flagship and high-tier Qualcomm(R)
Snapdragon(TM) 888 and 778G 5G Mobile Platforms to help bring
native, machine learning-driven vocal biomarker capabilities to
mobile and IoT devices globally. The optimization has the potential
to unlock several native health screening and monitoring
applications on up to the hundreds of millions of mobile devices
that use these Snapdragon mobile platforms.
The full text of the announcement from Sonde is as follows:
Sonde Health Vocal Biomarker Technology Optimized on Qualcomm
Snapdragon Mobile Platforms
BOSTON - July, 8 2021 - Sonde Health announced that it will work
with leading chipmaker Qualcomm Technologies, Inc. to optimize
Sonde's vocal biomarker technology for use with the flagship and
high-tier Qualcomm(R) Snapdragon(TM) 888 and 778G 5G Mobile
Platforms to help bring native, machine learning-driven vocal
biomarker capabilities to mobile and IoT devices globally. The
optimization has the potential to unlock several native health
screening and monitoring applications on hundreds of millions of
mobile devices that use these Snapdragon mobile platforms.
"Imagine a car that can detect whether a driver is too impaired
to drive safely, or a home hub that can detect the onset of
depression, or a phone that can make continuous asthma assessments.
Bringing the vocal biomarker technology directly into mobile
hardware will make new health features more useful and secure,"
said David Liu, CEO at Sonde Health. "This collaboration marks a
tremendous boost to our growth strategy, a vote of confidence in
our technology, and a giant leap forward for preventive and
personalized health care."
Sonde will work with Qualcomm Technologies to introduce Sonde's
capabilities and technology concept to Qualcomm Technologies'
mobile and IoT customers as part of the collaboration.
Sonde Health is a leading innovator in the field of vocal
biomarker technology, which uses audio signal processing and
machine learning to identify changes in the human voice that may be
indicative of a health condition. With a 6-second voice sample,
Sonde's product, Sonde One , can detect symptoms of asthma, COPD,
and other respiratory illnesses, and can be used as an early
warning system for COVID-19. Sonde Health's self-serve API/Software
Development Kit lets developers quickly integrate the company's
voice-enabled system check into Android and iOS applications.
With Sonde's technology optimized for use with Snapdragon 888
and 778G, device makers can enable vocal biomarker monitoring as a
device feature for their users. And because the capability is
native to the device, users simply opt-in to allow voice processing
to occur in the phone. This eliminates the need to send health data
to the cloud. The result is faster, more secure results with a
reduced adherence burden on patients.
"Patients with chronic conditions like asthma aren't going to
have to painstakingly log in their daily respiratory diaries.
They'll be able to continuously monitor their health without a
watch, ring, or other wearable device, simply by doing what they
normally do on their phone," Liu said.
For OEMs (Original Equipment Manufacturers) in the mobile device
and IoT industries, native vocal biomarker capabilities can provide
a crucial differentiator that helps protect the health and safety
of consumers.
"We are excited to talk to OEMs to explore new ways to deploy
innovative health monitoring capabilities that users will soon come
to expect from their web-enabled products," Liu said.
About Sonde Health
Leveraging over 1 million voice samples from 80,000+
individuals, Sonde Health's proprietary voice-based technology
platform is designed to detect changes of health conditions - like
mental fitness and respiratory disease - from changes in voice.
Using advanced audio signal processing and machine learning, Sonde
senses and analyzes subtle vocal changes due to changes in a
person's physiology to provide early health detection and
monitoring.
Sonde One, its health screening app, helps large organizations
to execute a daily population screening regimen that can help
reduce the spread of COVID-19, comply with government mandates, and
return to work safely. Sonde also has broad intellectual property
coverage worldwide and licenses its technology through its API
platform. www.sondehealth.com
About PureTech Health
PureTech is a clinical-stage biotherapeutics company dedicated
to discovering, developing and commercializing highly
differentiated medicines for devastating diseases, including
inflammatory, fibrotic and immunological conditions, intractable
cancers, lymphatic and gastrointestinal diseases and neurological
and neuropsychological disorders, among others. The Company has
created a broad and deep pipeline through the expertise of its
experienced research and development team and its extensive network
of scientists, clinicians and industry leaders. This pipeline,
which is being advanced both internally and through PureTech's
Founded Entities, is comprised of 26 therapeutics and therapeutic
candidates, including two that have received FDA clearance and
European marketing authorization, as of the date of PureTech's most
recently filed Annual Report on Form 20-F. All of the underlying
programs and platforms that resulted in this pipeline of
therapeutic candidates were initially identified or discovered and
then advanced by the PureTech team through key validation points
based on the Company's unique insights into the biology of the
brain, immune and gut, or BIG, systems and the interface between
those systems, referred to as the BIG Axis.
For more information, visit www.puretechhealth.com or connect
with us on Twitter @puretechh.
Cautionary Note Regarding Forward-Looking Statements
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments, and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, expectations regarding the collaboration between Sonde and
Qualcomm, including the expected optimization of Sonde's vocal
biomarker technology, expectations regarding the potential of
Sonde's vocal biomarker technology, including use on the Snapdragon
mobile platforms, expectations regarding the validation of Sonde's
technology, expectations regarding the potential benefits to
patients from the collaboration and those risks and uncertainties
described in the risk factors included in the regulatory filings
for PureTech Health plc. These forward-looking statements are based
on assumptions regarding the present and future business strategies
of the company and the environment in which it will operate in the
future. Each forward-looking statement speaks only as at the date
of this press release. Except as required by law and regulatory
requirements, neither the company nor any other party intends to
update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.
Contact:
Investors EU media
Allison Mead Talbot Ben Atwell, Rob Winder
+1 617 651 3156 +44 (0) 20 3727 1000
amt@puretechhealth.com ben.atwell@FTIconsulting.com
Qualcomm and Snapdragon are trademarks or registered trademarks
of Qualcomm Incorporated.
Qualcomm Snapdragon is a product of Qualcomm Technologies, Inc.
and/or its subsidiaries.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
Reach is a non-regulatory news service. By using this service an
issuer is confirming that the information contained within this
announcement is of a non-regulatory nature. Reach announcements are
identified with an orange label and the word "Reach" in the source
column of the News Explorer pages of London Stock Exchange's
website so that they are distinguished from the RNS UK regulatory
service. Other vendors subscribing for Reach press releases may use
a different method to distinguish Reach announcements from UK
regulatory news.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAEANXXEASFEFA
(END) Dow Jones Newswires
July 08, 2021 09:05 ET (13:05 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jun 2024 to Jul 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Jul 2023 to Jul 2024